Preclinical data shows spectinamide MBX-4888A can replace linezolid in the Nix-TB regimen, suggesting improved treatment for tuberculosis.
Spectinamides have garnered interest as experimental tuberculosis therapeutics owing to their safety profile and efficacy as partner agents when used in conjunction with established regimens in mice. The Nix-TB regimen of bedaquiline, pretomanid, and linezolid represents a short, effective regimen recommended for treatment of pre-extensively drug-resistant tuberculosis. However, linezolid administration is associated with severe adverse events which limits its use. Here we present preclinical data that spectinamide MBX-4888A can replace linezolid in Nix-TB.
No takes yet. Share an insight, caveat, or question.
Peroutka‐Bigus et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: